Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
The vast majority of sudden infant death syndrome (SIDS) cases are not the result of genetic heart diseases (GHDs) or a single genetic cause…
From - Diagnostic Testing & Emerging Technologies
Researchers have developed the first multiplex array for diagnosis of tickborne diseases, according to a study published online…
Recent report examining 10,000 claims to understand the key drivers of medical malpractice suits found 52 percent involved lab-related errors.
From - Diagnostic Testing & Emerging Technologies
New Recommendations Simplify Testing for Chronic Kidney Disease
In late February, The National Kidney Foundation, the American Society for Clinical Pathology, and leading laboratories and…
From - Diagnostic Testing & Emerging Technologies
There is not enough evidence, currently, to support the routine adoption of liquid biopsy tests for any of its promising clinical uses, according to a joint review published…